Fabtech Technologies IPO

About Fabtech Technologies IPO

The offer consists of a fresh issue component. The fresh issue will include 1,20,60,000 shares (aggregating up to ₹230.35 crores). The total number of shares is 1,20,60,000 shares and the aggregate amount is ₹230.35 crore.

The Fabtech Technologies IPO opens on Sep 29, 2025 and closes on Oct 1, 2025. The allotment date is Oct 3, 2025. The initiation of refunds will take place on Oct 6, 2025. The tentative listing date is Oct 7, 2025.

Fabtech Technologies Limited is a key turnkey engineering solution provider in the pharmaceuticals capex space, offering comprehensive start-to-finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. (Source: CRISIL Report). They offer services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sectors across various geographies, particularly key emerging economies. In such projects, they offer end-to-end turnkey engineering services which range from disease identification until installation and commissioning of equipment. Additionally, they also offer some of their engineering solutions, which majorly include equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects.

Objectives of Fabtech Technologies IPO

• Funding working capital requirements of the company.
• Pursuing inorganic growth initiatives through acquisitions.
• General Corporate Purpose

Industry Outlook

The Indian pharmaceutical industry is the world’s third largest by volume and was valued at ₹4,50,000 crores (including bulk drugs and formulation exports) as of fiscal 2025. India accounts for ~3.5% of total drugs and medicines exported globally, and exports pharmaceuticals to more than 200 countries and territories, including highly regulated markets such as the US, the UK, the European Union and Canada. India has a complete ecosystem for the development and manufacturing of pharmaceuticals, with companies having state-of-the-art facilities and skilled technical manpower.

Cumulative capex in the global pharmaceuticals industry was ~$37,000-42,000 crores over 2020 to 2024. During this period, the capex of pharmaceutical companies as a percentage of their revenue remained between 5.0-6.0%. Global pharmaceutical capex is estimated to increase 1.3x and witness cumulative capex investments of $50,000-55,000 crores between 2025 and 2029, owing to sustained capex investments due to the expiration of patents, increasing generic medicines usage and pricing pressures.

Fabtech Technologies Company Information

Fabtech Technologies Limited is a global company headquartered in India, specialising in turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies. Their footprint spans more than 62 countries: the Middle East, Africa, Asia, Europe, Latin America, North America, etc. Their company has a presence across some of the key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, the Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, the UAE, the USA and Tanzania. (Source: CRISIL Report). They provide extensive technical expertise and infrastructure to deliver comprehensive solutions for establishing aseptic manufacturing facilities, encompassing everything from design to certification.

They offer comprehensive start-to-finish services in greenfield projects, encompassing disease identification, planning, designing, engineering, procurement, quality assurance, logistics management, and installation and commissioning for a wide range of customers across various geographies, particularly key emerging economies. Additionally, they also offer some of their engineering solutions, which majorly include equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. In such projects, the feasibility study, design and engineering and other execution functions are undertaken by third-party solution providers, and their scope is limited to equipment supply or any other services required by their customers.

They are a part of the Fabtech Group, which was established in 1995 and has over twenty-nine (29) years of operating history in executing pharmaceutical turnkey projects. The company, Fabtech Technologies Limited, was incorporated in 2018 as Globeroute Ventures Private Limited.

Strengths of Fabtech Technologies IPO

• A key turnkey engineering solution provider offering integrated engineering solutions with comprehensive service offerings.
  
• Asset-light and integrated business model.
  
• In-house software technology capabilities.
  
• Diversified order book across geographies, clients, and business verticals.
  
• Project execution across diverse and challenging geographies.
  
• Efficient lead funnelling leading to higher mandate conversion.
  
• Track record of executing projects across all dosage forms.
  
• Experienced leadership team with Fabtech Group parentage.
  

Risks of Fabtech Technologies IPO

• Interruptions in the supply of equipment or supply of sub-standard equipment by their suppliers.
  
• Any adverse changes in economic and political conditions in the countries forming part of the Gulf Cooperation Council (“GCC”), Middle East and North African (“MENA”) and Economic Cooperation Organization (“ECO”) regions, where the majority of their ongoing and completed projects are located.
  
• Inability to successfully manage their geographically diverse operations.
  
• Factors that adversely affect the pharmaceuticals, healthcare and biotech sectors.
  
• Restrictions on work permits and travel or delay in arranging visas.
  
• Any failure arising from the non-performance, late performance or poor performance by third parties, or failure by third parties to comply with applicable laws.
  
• Foreign currency exchange rate fluctuations.
  
• Competition from other engineering companies offering specialised turnkey engineering solutions in the pharmaceutical, healthcare and biotechnology industry.
  
• Inability to obtain, renew or maintain their statutory and regulatory permits and approvals required to operate their businesses.
  

Peer Comparison

There are no listed companies in India that are of comparable size, from the same industry and with similar business model as that of our Company

Anchor Investor Bidding Date: Friday, 26 September 2025

Registrar: Bigshare Services Private Limited Book Running Lead Managers: Unistone Capital Private Limited

Business Model

The company earns its revenue through:

• Delivering customised, aseptic manufacturing solutions across 62+ countries, focusing on emerging markets and complex project needs.
  
• The company provides end-to-end project execution, including design, procurement, installation, and testing of pharmaceutical equipment, ensuring seamless and customized solutions.
  
• Offering customised, project-specific solutions ensuring optimal resource use and successful implementation, driving revenue through comprehensive engineering and certification services.
  

Fabtech Technologies Company Growth Trajectory

The total income increased by ₹105.34 crores, or 45.68%, from ₹230.60 crores in fiscal 2024 to ₹335.94 crores in fiscal 2025. This increase was primarily due to a rise in revenue from operations.

Revenue from operations increased by ₹100.53 crores, or 44.46%, from ₹226.14 crores in fiscal 2024 to ₹326.67 crores in fiscal 2025. The increase was due to: Sale of Products, Sale of Services, and Export Incentives.

Other income increased by ₹4.81 crores, or 107.55%, from ₹4.47 crores in fiscal 2024 to ₹9.27 crores in fiscal 2025. Reasons for the increase include: Interest Income, Foreign Exchange Gains, Reversal of provision for doubtful debts and advances, and Net gain arising on financial assets designated as FVTPL.

For the various reasons discussed above, profit for the year increased by ₹19.24 crores, or 70.67%, from ₹27.22 crores in fiscal 2024 to ₹46.45 crores in fiscal 2025. Profit after tax as a percentage of total income stood at 13.83% for fiscal 2025, compared to 11.80% for fiscal 2024.

Company Market Position

The company’s footprint spans more than 62 countries: the Middle East, Africa, Asia, Europe, Latin America, North America, etc. Their company has a presence across some of the key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, the Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, the UAE, the USA and Tanzania (Source: CRISIL Report).

The company has a track record of executing projects across diverse and challenging geographical landscapes. Owing to their international operations, particularly in emerging economies, they have developed the capabilities to successfully deliver projects in regions where conditions are less than favourable, on account of regional conflicts, disruption in supply chains, difficulty in recruiting skilled employees, etc. (Source: CRISIL Report).

As of 31 March, 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹335.942 crores, ₹46.453 crores, and ₹47.279 crores, respectively.

How to check the allotment status of Fabtech Technologies IPO?

1. Visit the Registrar's Website

To check the IPO allotment status for Fabtech Technologies Limited IPO, visit the official website of Bigshare Services Private Limited, the registrar for this IPO. On their IPO allotment status page, enter your Permanent Account Number (PAN), application number, or Demat account ID. Then, click the ‘Submit’ button to view your allotment status. Ensure you have the necessary details ready for a quick and accurate check.

2. Check on the Bombay Stock Exchange Website

The Bombay Stock Exchange (BSE) also has an IPO allotment status page. Go to the BSE website and find the 'Investors' tab. Under 'Investors', click on 'IPO'. This will take you to the IPO allotment status page.

On the BSE IPO page, follow these steps

• Select 'Equity' from the dropdown menu
  
• Choose 'Fabtech Technologies Limited' in the next dropdown
  
• Enter your application number
  
• Enter your PAN
  
• Click 'Search'
  

Your Fabtech Technologies Limited IPO allotment status will be displayed.

3. Verify on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. Use this to check Fabtech Technologies Limited IPO allotment status.

Go to the NSE website and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.
On the NSE IPO Bid Verification page, enter:

• Application number
  
• PAN
  

Then click 'Submit'. Your Fabtech Technologies Limited IPO bid and allotment details will be displayed.

How to apply for the Fabtech Technologies Limited IPO?

• Step 1: Log in to your Kotak Securities Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
  
• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
  
• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
  
• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
  
• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.